+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


The Global Immuno-oncology Therapeutics Market - Checkpoint Inhibitors

  • ID: 3785481
  • Report
  • July 2016
  • Region: Global
  • 127 Pages
  • Frost & Sullivan
The Next Generation of Cancer Therapies


  • AstraZeneca
  • Keytruda®
  • Merck KGaA
  • Opdivo®
  • Tecentriq®
  • Yervoy®
  • MORE
Immuno-oncology is based on the premise that tumors escape detection by the immune system, contributing to their growth and progression. Checkpoint inhibitor pathways act as the checks and balances that allow T-cells to recognize foreign substances or tumors. This global study looks at the immune-oncology therapeutics pipeline for checkpoint inhibitors in the drug classes CTLA-4, PD-1/PD-L1, LAG-3, and TIM-3, identifying companies and products in development, dollars spent at each phase (preclinical through launch), cost and reimbursement implications to payers, challenges to commercialization, and opportunities for pharmaceutical, biotech, or diagnostic companies as oncology treatment algorithms evolve. The study period is 2011 to 2020.

Key Questions this Study will Answer

- What checkpoint therapies are in development and for what indications?
- What products and indications will be launched in the next 5 years?
- Who is investing in the development of checkpoint inhibitors, at what phase, and at what level of deal funding?
- What are some of the cost implications for checkpoint therapies, especially when combined with other immuno-oncology therapies?
- What are the challenges to development and commercialization of checkpoint inhibitors?
- What challenges do payers face related to the high cost of specialty therapeutics?
Note: Product cover images may vary from those shown


  • AstraZeneca
  • Keytruda®
  • Merck KGaA
  • Opdivo®
  • Tecentriq®
  • Yervoy®
  • MORE
1. Executive Summary-Checkpoint Inhibitors

Scope and Segmentation
Key Questions this Study will Answer
Key Takeaways
Market Snapshot
8 Big Market Themes for Checkpoint Inhibitors
A Vibrant Ecosystem
Paradigm Expansion to Solid Tumor Cancer Therapies
Regional Launch Highlights
Game-changing Companies
Significant Investor Funding
Key 2016 Predictions-Checkpoint Inhibitor Market

2. Disruptive Pipeline Analysis

Key Methodology and Scope
Checkpoint Inhibitor Drug Classes
Timeline of Checkpoint Product Approvals
Competitive Landscape-Target Segments, Count of Marketed and Pipeline Products
Checkpoint Segmentation by Subtype
Competitive Landscape-Target Product Counts by Phase

3. Competitive Landscape

Checkpoint Pipelines by Company, Target, and Phase
Checkpoint Target Segmentation
Competitive Landscape-CTLA-4/CAIX/GITR Segment, Products in Development
Competitive Landscape-PD-1/PD-L1 (programmed death 1-receptor)
Competitive Landscape-LAG-3 (lymphocyte activating gene 3)
Competitive Landscape-TIM-3 (T-cell immunoglobin and mucin domain 3)

4. Product Dashboards of Leading Checkpoint Inhibitors

PD-1 Product Dashboard-Keytruda® (Pembrolizumab): Merck & Co. (Marketed)
PD-1 Product Dashboard-Opdivo® (Nivolumab): Bristol-Myers Squibb/Ono (Marketed)
CTLA-4 Product Dashboard-Yervoy® (ipilimumab): Bristol-Myers Squibb (Marketed)
PD-L1 Product Dashboard-Tecentriq® (Atezolizumab): Roche (Marketed)

5. Key Companies and Products to Watch by Target

Competitive Overview of Established Companies
Checkpoint Inhibitors-PD-1/PD-L1
PD-L1 Product Dashboard-Avelumab (MSB0010718C): Merck KGaA (Phase III)
PD-L1 Product Dashboard-Durvalumab (MEDI-4736): AstraZeneca / MedImmune (Phase III)
Checkpoint Inhibitors-CTLA-4
CTLA-4 Product Dashboard-Tremelimumab (MEDI-1123): AstraZeneca (Phase III)

6. Opportunities in Combination Therapies

Immuno-oncology Combination Therapies
Checkpoint Combination Clinical Trials by Indication
Immuno-oncology Checkpoint Phase III Trials to Watch
Disruptive Technologies and Advances in this Field

7. Commercialization Analysis

Market Opportunities
Potential Game-changing Therapies
Overall Environmental Impact Factors
Checkpoint Product Patent Expirations

8. Commercialization Analysis-Biomarkers

Biomarker Challenges

9. Commercialization Analysis-Cost Considerations

Opportunities in this Market-Escalating Drug Costs
Checkpoint Inhibitor Payer Environment
J-Codes, Annual Costs, and US Payers
Reimbursement Pathway-On-label Reimbursement Path
Reimbursement Pathway-Off-Label, Medicare
Reimbursement Pathway-Off-Label, Commercial Payers
A Snapshot of Global Drug Price Control Methods
Pitfalls to Avoid

10. Commercialization Analysis-Key Companies and Products to Watch

Companies to Watch
Checkpoint Inhibitor Forecast Sales Total-2020 ($20.5B)Actual Sales by Product

11. Commercialization Analysis-Funding Considerations

Investors Pour in Significant Funds
Checkpoint Milestones
2015 Deal and Financing-CTLA-4 Receptor Gene Therapy
2015 Deal and Financing Summary-PD-1/PD-L1
2015 Deal and Financing Summary-LAG-3
2015 Deal and Financing Summary-TIM-3

12. Conclusion and Take Home Points

Key Conclusions
Growth Opportunities in 4 Checkpoint Inhibitor Segments
New Market Opportunities-Checkpoint Inhibitors
The Last Word-3 Big Predictions
Legal Disclaimer

13. Appendix-Checkpoint Inhibitors Development Pipeline Summaries

Pipeline Analysis-CTLA-4/CAIX/GITR Segment, Products in Development
Pipeline Analysis-LAG-3 Products in Development
Pipeline Analysis-PD-1/PD-L1 Segment, Products in Development
Pipeline Analysis-TIM-3 (T-cell immunoglobin and mucin domain 3) Segment, Products in Development
Note: Product cover images may vary from those shown
- AstraZeneca
- Keytruda®
- Merck KGaA
- Opdivo®
- Tecentriq®
- Yervoy®

Note: Product cover images may vary from those shown